

Erythropoietin - Literature:

1. **Mittelman M**, Zeidman A, Bendayan D, Magazanik A, Lewinski UH, Cohen AM: Recombinant human erythropoietin in the treatment of multiple myeloma associated anemia. *Acta Haematologica* 98: 204-10, 1997.
2. **Mittelman M**, Neumann D, Peled A, Kanter P, Haran-Ghera N: Erythropoietin induces tumor regression and anti-tumor immune responses in murine myeloma models. *Proceedings of The National Academy of Sciences of the USA*, 98: 5181-5186, 2001.
3. **Mittelman M**: Epoetin Alfa induces tumor regression and anti-tumor immune responses in a murine myeloma model; In: Update on anemia related to hematologic malignancies. *The Oncologist* 8: 6, 2003.
4. **Mittelman M**: The implications of anemia in multiple myeloma. *Clinical Lymphoma* 4 (Suppl 1): S23-29, 2003.
5. **Mittelman M**, Zeidman A, Kanter P, Katz O, Oster H, Rund D, Neumann D: Erythropoietin has an anti-myeloma effect – a clinical observation supported by animal studies. *European Journal of Haematology* 72: 155-165, 2004.
6. **Mittelman M**, Zeidman A, Kanter P, et al: Antimyeloma effect of erythropoietin: support from animal studies. **Focus On Anaemia In Cancer** 6:20-21, 2005.
7. Boogaerts M, **Mittelman M**, Vaupel P: Beyond Anaemia Management: Evolving Role of Erythropoietin Therapy in Neurological Disorders, Multiple Myeloma and Tumour Hypoxia Models. *Oncology*,69: 22-30, 2005.
8. Prutchi-Sagiv S, Neumann D, **Mittelman M**: Erythropoietin as an immunotherapeutic agent: new uses for an old drug? **Medical Hypotheses And Research** 2:587-596, 2005.
9. Katz O, Barzilay E, Skaat A, Herman A, **Mittelman M**, Neumann D. Erythropoietin induced tumour mass reduction in murine lymphoproliferative models. *Acta Haematologica*. 114(3): 177-9 2005.
10. Prutchi-Sagiv S, Golishevsky N, Oster HS, Katz O, Cohen A, Naparstek E, Neumann D, **Mittelman M**: Erythroopoitin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? **British Journal Of Haematology** 135: 660-672, 2006.
11. Oster H, Hoffman M, Prutchi-Sagiv S, Katz O, Neumann D, **Mittelman M**: Erythropoietin in Clinical Practice: Current Use, Effect on Survival, and future Directions. **Isr Med Assoc J** 8: 703-706, 2006
12. **Mittelman M**, Oster H,S, Katz O, Prutshi-Sagiv S, Hoffman M, Neumann D: Does erythropoietic treatment influence the survival of patients with multiple myeloma ? **Focus On Anaemia In Cancer** 7:23-25, 2006.
13. Katz O, Gill L, Lifshitz L, Prutchi-Sagiv S, Gassmann M, **Mitte lman M**, Neumann D: Erythroppietin enhances immune responses in mice. **Eur J. Immunol** 37:1584-1593 2007.
14. Prutchi-Sagiv S, Gadassi N, Oster HS, Naparstek E, Cohen AM, Hardan I, Neumann D, **Mittelman M**: Elevated normal immunoglobulins in multiple myeloma patients receiving erythropoietin (ASH 2007).
15. Lifshitz L, Prutchi-Sagiv S, Markovitz M, **Mittelman M**, Neumann D: Dendritic cells as a novel target for erythropoietin: Studies in murine

- models. The 49th American Society of Hematology – Annual Meeting, Dec 2007, Atlanta GA, Blood 2007 (Suppl) 110: 713a, Abs # 2417, Poster # 607-II.
16. Prutchi-Sagiv S, Lifshitz L, Orkin R, **Mittelman M***, Neumann D: Erythropoietin effects on dendritic cells: Potential mediators in its function as an immuno-modulator ? **Experimental Hematology** 36: 1682-1690, 2008 (* equal contribution as DN).
 17. Lifshitz L, Prutchi-Sagiv S, Avneon M, Gassmann M, **Mittelman M***, Neumann D: Non Erythroid activities of erythropoietin: Functional effects on murine dendritic cells. **Molecular Immunology** 46: 713-721, 2009 (* equal contribution as DN).
 18. Avneon M, Lifshitz L, Katz O, Prutchi-Sagiv S, Gassmann M, **Mittelman M***, Neumann D: Non-erythroid effects of erythropoietin: are neutrophils a target ? **Leukemia Research** 33: 1430-1432, 2009. (* equal contribution as DN).
 19. Lifshitz L, Berger A, **Mittelman M**, Neumann D: Erythropoietin and cyclophosphamide combination treatment additively enhances antibody production in mice. **Acta Haematol** 123: 81-3, 2010.
 20. Katz O, Stuible M, Golishevsky N, Lifshitz L, Tremblay ML, Gassmann M, **Mittelman M**, Neumann: Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine models. **Journal of Endocrinology** 205: 87-95, 2010.
 21. Lifshitz L, Tabak G, Gassmann M, **Mittelman M**, Neumann D: Macrophages as novel target cells for erythropoietin. **Haematologica** 95: 1823-31, 2010.
 22. Neumann D, Prutchi-Sagiv S, Lifshitz L, **Mittelman M**: Erythropoietin receptor is detectable on peripheral blood lymphocytes and its expression increases in activated T lymphocytes (reply). **Haematologica** 96: e 14, 2011 (Letter).
 23. Oster HS, Neumann D, Hoffman M, **Mittelman M**: Erythropoietin: the swinging pendulum. **Leukemia Research**: 36: 939-44, 2012
 24. Oster H. S., Prutchi-Sagiv S., Halutz O., Shabtai E., Hoffman M., Neumann D., **Mittelman M**. Erythropoietin treatment is associated with an augmented immune response to the influenza vaccine in hematologic patients. **Experimental Hematology** 41: 167-171, 2013.
 25. Oster HS, Benderly M, Hoffman M, **Mittelman M**: Anemia is common in patients with congestive heart failure – even mild anemia is associated with increased mortality: The results of a national study (**IMAJ**).
 26. Suttorp M.M., Hoekstra T., **Mittelman M.**, Ott I., Franssen C., Dekker F. Effect of Erythropoiesis – stimulating agents on blood pressure in pre-dialysis patients. (CJASN) 0634-06-13, 14/06/2013
 27. Suttorp MM, Hoekstra T., Rotmans J. I., Ott I., **Mittelman M.**, Krediet R. T., Dekker F. W. ESA resistance is associated with mortality in hemodialysis and peritoneal dialysis patients (Clinical Journal of the American Society of Nephrology).